Sunitinib‐Induced Cardiotoxicity Is Mediated by Off‐Target Inhibition of AMP‐Activated Protein Kinase

Tyrosine kinase inhibitors (TKIs) are transforming the treatment of patients with malignancies. One such agent, sunitinib (Sutent, Pfizer, New York, NY, USA), has demonstrated activity against a variety of solid tumors. Sunitinib is “multitargeted,” inhibiting growth factor receptors that regulate b...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Kerkela, Risto, Woulfe, Kathleen C., Durand, Jean‐Bernard, Vagnozzi, Ronald, Kramer, David, Chu, Tammy F., Beahm, Cara, Chen, Ming Hui, Force, Thomas
Médium: Artigo
Jazyk:Inglês
Vydáno: Blackwell Publishing Inc 2009
Témata:
Research Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2849142/
https://ncbi.nlm.nih.gov/pubmed/20376335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1752-8062.2008.00090.x
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky